Abstract
Merkel Cell carcinoma (MCC) is a rare but aggressive cancer, with an estimated disease-associated mortality as high as 46%. MCC has proven to be an immunologically responsive disease and the advent of immune checkpoint inhibitors has changed the treatment landscape for patients with advanced MCC. In this review, we discuss the rationale for the use of immune checkpoint inhibition, review current single agent therapies tested in and approved for MCC, and discuss emerging immunotherapeutic options for these patients.
| Original language | English (US) |
|---|---|
| Article number | 23 |
| Journal | Journal for ImmunoTherapy of Cancer |
| Volume | 6 |
| Issue number | 1 |
| DOIs | |
| State | Published - Mar 23 2018 |
| Externally published | Yes |
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology
- Molecular Medicine
- Oncology
- Pharmacology
- Cancer Research